RAMM Pharma Corp. Receives Minority Shareholder Approval for Proposed Investment Transaction with The Global South S.A.S.

Core Points - RAMM Pharma Corp. has received approval from its minority shareholders for a proposed investment transaction with The Global South S.A.S. [1] - The transaction involves a US$5 million investment for a 10% equity interest in The Global South, with a post-investment valuation of US$50 million [2] - RAMM will have a call option to acquire an additional 15% equity interest, potentially increasing its total ownership to 25% at a future valuation of US$400 million [2] - The completion of the transaction is contingent upon negotiation of definitive documentation and receipt of regulatory approvals [3] Company Overview - RAMM Pharma is engaged in cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and hemp products, with a diversified international production and sales platform [4] - The company's operations in Europe include extraction and processing facilities in Italy and Poland, with subsidiaries such as Canapar Corp. and HemPoland [5][6]